Rabkin C S, Hilgartner M W, Hedberg K W, Aledort L M, Hatzakis A, Eichinger S, Eyster M E, White G C, Kessler C M, Lederman M M
Viral Epidemiology Section, National Cancer Institute, Rockville, MD 20852.
JAMA. 1992 Feb 26;267(8):1090-4.
To determine the types and rates of cancers occurring in excess in the presence of infection with the human immunodeficiency virus type 1 (HIV-1).
Cohort analytic study of HIV-infected and HIV-uninfected subjects followed for up to 12 years.
Fifteen hemophilia treatment centers.
A total of 1701 patients with hemophilia, of whom 1065 (63%) were HIV-1 seropositive.
Morphologic classification and incidence rates of cancers.
The incidence of non-Hodgkin's lymphoma after HIV seroconversion averaged 0.15 case per 100 person-years (95% confidence interval [CI], 0.08 to 0.25) and rose exponentially with increasing duration of HIV infection. Although the greatest absolute risk of lymphoma was in the oldest age group, the relative increase compared with general population rates was 38-fold in subjects 10 to 39 years old and 12-fold in older subjects (P less than .05). The CD4+ T-lymphocyte levels for lymphoma cases were similar to HIV-positive subjects without the acquired immunodeficiency syndrome (AIDS) who had been infected for the same length of time. The incidence of Kaposi's sarcoma was increased 200-fold (95% CI, 20 to 700). The incidence of cancers other than non-Hodgkin's lymphoma and Kaposi's sarcoma were not increased in the HIV-positive subjects (ratio of observed to expected cases, 0.9 [95% CI, 0.4 to 1.9]). The HIV-negative subjects had no significant increase in cancer incidence.
HIV infection has restricted effects on cancer incidence that are only partly explained by immunosuppression. Paradoxically, improvements in therapy of HIV infection that prolong survival may lead to further increases in HIV-associated lymphoma.
确定在感染1型人类免疫缺陷病毒(HIV-1)的情况下额外发生的癌症类型和发生率。
对HIV感染和未感染的受试者进行长达12年的队列分析研究。
15个血友病治疗中心。
总共1701例血友病患者,其中1065例(63%)HIV-1血清学呈阳性。
癌症的形态学分类和发病率。
HIV血清转化后非霍奇金淋巴瘤的发病率平均为每100人年0.15例(95%置信区间[CI],0.08至0.25),并且随着HIV感染持续时间的增加呈指数上升。尽管淋巴瘤的绝对风险在年龄最大的组中最高,但与一般人群发病率相比,10至39岁受试者的相对增加为38倍,年龄较大的受试者为12倍(P<0.05)。淋巴瘤病例的CD4+T淋巴细胞水平与感染相同时间但无获得性免疫缺陷综合征(AIDS)的HIV阳性受试者相似。卡波西肉瘤的发病率增加了200倍(95%CI,20至700)。HIV阳性受试者中非霍奇金淋巴瘤和卡波西肉瘤以外的癌症发病率没有增加(观察病例与预期病例的比率为0.9[95%CI,0.4至1.9])。HIV阴性受试者的癌症发病率没有显著增加。
HIV感染对癌症发病率的影响有限,免疫抑制只能部分解释这种影响。矛盾的是,延长生存期的HIV感染治疗改善可能会导致HIV相关淋巴瘤的进一步增加。